ERBB2 and breast carcinoma: APHINITY investigated the role of dual blockade in the adjuvant setting in HER2+ early breast cancer with node-positive disease or node-negative disease with tumours > 1.0 cm in patients who were chemotherapy- and anti-HER2-antibody-naïve (i.e., no neoadjuvant therapy) [40].